{"id":212724,"name":"IGM BIOSCIENCES, INC.","slug":"igm-biosciences-inc","state":"CA","country":"United States of America","description":"","totalSpending":1980000,"filings":14,"yearlySpending":[{"year":2021,"income":140000},{"year":2022,"income":660000},{"year":2023,"income":930000},{"year":2024,"income":250000}],"issues":[{"code":"MED","display":"Medical/Disease Research/Clinical Labs"}],"firms":["IGM BIOSCIENCES, INC."],"lobbyists":["ANDREW WOMACK"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","Executive Office of the President (EOP)"],"sampleDescriptions":["Issues relating to the development of antibody therapy for COVID-19","Issues relating to the development of antibody therapy for COVID-19.\nIssues related to supply chain and biopharmaceutical manufacturing.","H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to t","H.R.2471 - Consolidated Appropriations Act, 2022 COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to t","COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-1"]}